BARBIERI, Lucia
 Distribuzione geografica
Continente #
EU - Europa 1.000
NA - Nord America 955
AS - Asia 299
AF - Africa 2
Continente sconosciuto - Info sul continente non disponibili 2
SA - Sud America 2
Totale 2.260
Nazione #
US - Stati Uniti d'America 949
IE - Irlanda 315
DE - Germania 249
SE - Svezia 169
UA - Ucraina 129
CN - Cina 90
HK - Hong Kong 84
IN - India 48
IT - Italia 46
SG - Singapore 46
FI - Finlandia 39
FR - Francia 23
IR - Iran 18
GB - Regno Unito 11
VN - Vietnam 8
CA - Canada 6
CZ - Repubblica Ceca 5
PL - Polonia 5
JP - Giappone 3
NL - Olanda 3
EG - Egitto 2
EU - Europa 2
AT - Austria 1
CL - Cile 1
ES - Italia 1
KG - Kirghizistan 1
LT - Lituania 1
LU - Lussemburgo 1
MY - Malesia 1
NO - Norvegia 1
PE - Perù 1
RU - Federazione Russa 1
Totale 2.260
Città #
Dublin 315
Jacksonville 255
Dearborn 138
Wilmington 115
Hong Kong 84
Bremen 42
Lawrence 42
Princeton 42
Beijing 39
Chandler 38
Düsseldorf 35
Singapore 29
Ashburn 28
San Mateo 14
Woodbridge 14
Ann Arbor 11
Monmouth Junction 11
Hefei 9
Munich 9
Dong Ket 8
Leawood 8
Piemonte 8
Nanjing 7
Zanjan 7
Helsinki 6
Houston 6
Los Angeles 6
Seattle 6
Shenyang 6
Augusta 5
Brno 5
Norwalk 5
Ardabil 4
Cagliari 4
Fairfield 4
Kunming 4
Polska 4
Toronto 4
Andover 3
Chicago 3
Garland 3
Nanchang 3
Torino 3
Zhengzhou 3
Baotou 2
Cairo 2
Casalecchio Di Reno 2
Fuzhou 2
Gunzenhausen 2
League City 2
Mestre 2
New Delhi 2
Noicattaro 2
Quzhou 2
Redwood City 2
Sacramento 2
Salsomaggiore 2
San Francisco 2
Stockholm 2
Turin 2
Wenzhou 2
Winnipeg 2
Alvin 1
Bangalore 1
Berlin 1
Bishkek 1
Cambridge 1
Caserta 1
Changsha 1
Clearwater 1
Dallas 1
Des Moines 1
Erchie 1
Frankfurt am Main 1
Grafing 1
Guangzhou 1
Hangzhou 1
Harbin 1
Henderson 1
Jiaxing 1
Jinan 1
Lanzhou 1
Las Vegas 1
Lima 1
Luxembourg 1
Lvov 1
Milan 1
Modesto 1
Newark 1
Nürnberg 1
Pisa 1
San Filippo 1
Simi Valley 1
Wuhan 1
Xian 1
Zgierz 1
Totale 1.465
Nome #
Impact of 719 Trp>Arg polymorphism of KIF 6 gene on coronary artery disease, contrast induced nephropathy and modulation of statin therapy effectiveness 123
Impact of gender difference on vitamin D status and its relationship with the extent of coronary artery disease 72
Coronary intravascular ultrasound (IVUS): Contemporary applications and bases for the future 70
Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor 70
Acetylsalicylic acid desensitization in patients with coronary artery disease: A comprehensive overview of currently available protocols 69
Impact of high-dose statins on vitamin D levels and platelet function in patients with coronary artery disease. 68
Platelet HPA-1 a/HPA-1 b polymorphism and the risk of periprocedural myocardial infarction in patients undergoing elective PCI. 64
Relationship Between Glycoprotein IIIa Platelet Receptor Gene Polymorphism and Coronary Artery Disease 64
Platelet Larger Cell Ratio and High-on Treatment Platelet Reactivity During Dual Antiplatelet Therapy 63
Platelet-larger cell ratio and the risk of periprocedural myocardial infarction after percutaneous coronary revascularization. 62
Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: Rationale and design of the REDUCE trial 62
Impact of Diabetes on Homocysteine Levels and Its Relationship with Coronary Artery Disease: A Single-Centre Cohort Study 61
Impact of long-term dual antiplatelet therapy on immature platelet count and platelet reactivity. 61
Impact of diabetes on neutrophil-to-lymphocyte ratio and its relationship to coronary artery disease 60
Impact of age on mean platelet volume and its relationship with coronary artery disease: A single-centre cohort study 60
Bivalirudin as compared to unfractionated heparin in patients undergoing percutaneous coronary revascularization: A meta-analysis of 22 randomized trials 59
Glycosylated hemoglobin and the risk of periprocedural myocardial infarction in non-diabetic patients 58
Platelet PIA1/PIA2 polymorphism and the risk of periprocedural myocardial infarction in patients with acute coronary syndromes undergoing coronary angioplasty. 58
Impact of adenosine A2a receptor polymorphism rs5751876 on platelet reactivity in ticagrelor treated patients 58
Advanced age and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. 57
Neutrophil to Lymphocyte Ratio and the Extent of Coronary Artery Disease: Results from a Large Cohort Study 55
Diabetes mellitus, glucose control parameters and platelet reactivity in ticagrelor treated patients 55
Impact of high-dose statins on vitamin D levels and platelet function in patients with coronary artery disease. 55
High-Density Lipoproteins and Coronary Artery Disease: A Single-Center Cohort Study 55
Prevalence and predictors of high-on treatment platelet reactivity with ticagrelor in ACS patients undergoing stent implantation. 52
Impact of sex on uric acid levels and its relationship with the extent of coronary artery disease: A single-centre study 52
Impact of anticoagulation strategy with bivalirudin or heparin on nonaccess site bleeding in percutaneous coronary interventions: A meta-analysis of randomized trials 52
Impact of diabetes on fibrinogen levels and its relationship with platelet reactivity and coronary artery disease: A single-centre study 51
Impact of red blood cells count and high density lipoproteins with the prevalence and extent of coronary artery disease 51
Radial vs femoral approach in acute coronary syndromes: A meta-analysis of randomized trials 50
Dual Versus Single Antiplatelet Regimen With or Without Anticoagulation in Transcatheter Aortic Valve Replacement: Indirect Comparison and Meta-analysis 50
Optimal Duration of Dual Antiplatelet Therapy After DES Implantation: A Meta-Analysis of 11 Randomized Trials 48
Two catheters for one perforation 46
Impact of Long-Term Dual Antiplatelet Therapy on Immature Platelet Count and Platelet Reactivity 46
Risk and Benefits of Triple Therapy in Patients Undergoing Coronary Stent Implantation Requiring Oral Anticoagulation: A Meta-Analysis of 16 Studies 44
Impact of pre-procedural dual antiplatelet therapy on periprocedural myocardial infarction in patients undergoing percutaneous coronary interventions with adjunctive tirofiban. 44
Resting Pd/Pa and haemodynamic relevance of coronary stenosis as evaluated by fractional flow reserve 44
Impact of increasing dose of intracoronary adenosine on peak hyperemia duration during fractional flow reserve assessment 44
Impact of metabolic syndrome on mean platelet volume and its relationship with coronary artery disease 43
Switching from Clopidogrel to Prasugrel in patients undergoing PCI: A meta-analytic overview 41
Percutaneous Versus Surgical Revascularization for Left Main or Multivessel Coronary Artery Disease: Results From a Large-Scale Meta-Analysis in the Era of Drug-Eluting Stents 36
Impact of vascular access on the development of contrast induced nephropathy in patients undergoing coronary angiography and/or percutaneous coronary intervention 34
Totale 2.367
Categoria #
all - tutte 12.896
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.896


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020385 0 0 0 0 0 88 114 23 50 62 47 1
2020/2021282 43 2 42 0 42 4 42 0 43 12 42 10
2021/2022288 17 19 36 18 27 2 5 6 15 16 65 62
2022/2023622 44 27 47 4 54 45 14 44 307 0 24 12
2023/2024225 17 24 23 2 34 0 30 4 0 2 61 28
2024/202567 13 11 12 1 29 1 0 0 0 0 0 0
Totale 2.367